Information Library
North and Central America
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by:
- Most Recent
- Title
-
QUINTILES ANNOUNCES NEW EUROPEAN HEADQUARTERS
July 29, 2010 - Quintiles, announced that it is re-locating its European headquarters to within 30 minutes of Heathrow Airport at Green Park, Reading overlooking the M4 motorway.
-
QUINTILES ANNOUNCES CLINICAL RESEARCH PARTNERSHIP WITH THE UNIVERSITY MALAYA MEDICAL CENTRE
July 5, 2010 - Quintiles announces a strategic alliance agreement with the University Malaya Medical Centre (UMMC) as part of its unique Prime Site program - an initiative focused on accelerating the development of new and more effective medicines.
-
Clinical Trials: Race to Study Launch & Speed to Finish
July 2, 2010
Chris Cabell's presentation at DIA US 2010 - Clinical Trials:Race to Study Launch and Speed to Finish -
Malaysia Prime Site
July 2, 2010
Adam Chasse, Sr. Director, Access to Patients explains the importance of Prime Sites and the impact of our clinical research partnership with the University of Malaya Medical Centre in Malaysia. -
Promoting Adherence
July 1, 2010
In one of the longest running Quintiles HMS projects, nurse educators provide training on multiple sclerosis and therapy to new patients and their caregivers. -
THE NEW HEALTH REPORT REVEALS PERCEPTION GAPS AMONG BIOPHARMA STAKEHOLDERS
June 15, 2010 - Newly published report details the differences between bio pharma and other key stakeholders as they grapple with industry challenges.
-
THE NEW HEALTH REPORT FINDS GREATER INFLUENCE FOR PATIENTS ON DRUG DEVELOPMENT
June 15, 2010 - Patients are emerging as an increasingly strong group when it comes to influencing the success and failure of new drugs – according to a newly published New Health Report commissioned by Quintiles.
-
New Frontiers
June 8, 2010
By utilizing a deliberately flexible monitoring schedule, Quintiles was able to accommodate fluxes in enrollment and substantial variations in enrollment from site to site. -
QUINTILES ANNOUNCES SUITE OF PI3K BIOMARKER ASSAYS TO ADVANCE ONCOLOGY THERAPIES TARGETING THIS CANCER PATHWAY
June 7, 2010 - Suite is part of Quintiles Global Central Labs’ ongoing efforts to advance personalized medicine.
-
QUINTILES AND KAISER PERMANENTE ANNOUNCE ALLIANCE TO ACCELERATE DRUG DEVELOPMENT
May 18, 2010 - Quintiles is accelerating drug development with the addition of Kaiser Permanente's Southern California Permanente Medical Group to its global site program
